Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison
Three generations of incretin research peptides
Retatrutide, tirzepatide and semaglutide are the three most widely studied peptides in incretin and receptor research. They sit on a clear progression: each newer compound engages one additional metabolic receptor than the last. Semaglutide acts at a single receptor, tirzepatide at two, and retatrutide at three. For researchers, the practical question is not which is “best” but which receptor profile matches the pathway being studied.
This comparison is structured around receptor pharmacology — the dimension that actually distinguishes these compounds in a laboratory setting. It does not cover human dosing, efficacy or clinical outcomes, which fall outside the scope of research-reagent supply.
Side-by-side receptor comparison
| Property | Semaglutide | Tirzepatide | Retatrutide (LY3437943) |
|---|---|---|---|
| GLP-1 receptor agonism | ✓ | ✓ | ✓ |
| GIP receptor agonism | ✗ | ✓ | ✓ |
| Glucagon receptor agonism | ✗ | ✗ | ✓ |
| Receptor targets | 1 | 2 | 3 |
| Research generation | First generation | Second generation | Third generation (triple) |
| Primary research axis | Insulin secretion, satiety signalling | Added GIP-mediated insulin potentiation | Added glucagon-mediated energy expenditure |
The pattern is additive: tirzepatide builds on the GLP-1 mechanism of semaglutide by adding GIP receptor agonism, and retatrutide builds on that dual model by adding a third axis — glucagon receptor engagement, associated in animal models with hepatic glucose handling and energy expenditure.
Semaglutide — single GLP-1 agonist
Semaglutide is a GLP-1 receptor agonist — a single-receptor compound. In preclinical research, GLP-1 receptor activation is associated with glucose-dependent insulin secretion, reduced gastric emptying and appetite-signalling pathways in the central nervous system. As the simplest of the three mechanistically, semaglutide is often used as a baseline or reference compound when researchers want to isolate the GLP-1 pathway from GIP or glucagon contributions.
Tirzepatide — dual GLP-1 / GIP agonist
Tirzepatide engages both GLP-1 and GIP receptors. Research interest in dual GIP/GLP-1 agonism stems from evidence that the two pathways may act synergistically rather than redundantly.[2] For a research model investigating how GIP receptor activity modifies GLP-1 signalling, tirzepatide provides the two-receptor case that sits between single-agonist semaglutide and triple-agonist retatrutide.
Retatrutide — triple GLP-1 / GIP / glucagon agonist
Retatrutide (LY3437943) adds glucagon receptor agonism to the GLP-1/GIP dual model. In isolation, glucagon receptor activation raises blood glucose — the opposite of GLP-1 agonism — but the research rationale for combining it with GLP-1 and GIP agonism is the hypothesis that the net effect on energy expenditure and fat metabolism exceeds dual agonism, while glycaemic impact is modulated by the simultaneous insulin-secretion effects of the other two pathways.[1] This three-axis profile makes retatrutide the compound of choice for researchers studying combined incretin-receptor effects that cannot be reproduced with single or dual agonists.
For a deeper treatment of retatrutide’s mechanisms, study findings and laboratory handling, see the full Retatrutide research overview, or view the Retatrutide product page for HPLC-verified supply details.
Choosing a compound for a research model
The right compound depends on the receptor question being asked. To study the GLP-1 pathway in isolation, semaglutide is the cleanest single-receptor reference. To examine how GIP modifies GLP-1 signalling, tirzepatide provides the dual case. To investigate the full three-receptor interaction — including the glucagon axis — retatrutide is the only option of the three. Velox Peptides supplies all relevant incretin-pathway compounds as HPLC-verified lyophilised reagents with a batch certificate of analysis. Browse the full incretin & receptor research category for the complete range.
References
- Coskun T et al. “LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss.” Cell Metabolism, 2022. PMID: 35108511
- Finan B et al. “Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.” Science Translational Medicine, 2013. PMID: 24107776
- Jastreboff AM et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine, 2023. PMID: 37352492
